Clinical reasearch of bendamustine combination regimen in the treatment of relapsed/refractory multiple myeloma
10.3760/cma.j.cn431274-20210702-00719
- VernacularTitle:苯达莫司汀联合化疗方案治疗复发/难治性多发性骨髓瘤的临床观察
- Author:
Lei SHI
1
;
Minqiu LU
;
Shan GAO
;
Bin CHU
;
Yutong WANG
;
Qiuqing XIANG
;
Yuehua DING
;
Li BAO
Author Information
1. 北京积水潭医院血液科 100096
- Keywords:
Antineoplastic combined chemotherapy protocols;
Multiple myeloma, refractory;
Multiple myeloma, relapsing;
Bendamustine
- From:
Journal of Chinese Physician
2021;23(12):1822-1827
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy and safety of bendamustine combination regimen in the treatment of patients with relapsed or refractory multiple myeloma (RRMM).Methods:From March 2020 to December 2020, 16 patients with RRMM were treated with bendamustine combination regimen in Beijing Jishuitan Hospital. The efficacy and adverse events (AEs) of bendamustine combination regimen were retrospectively analyzed in the 16 patients.Results:The median treatment lines for 16 patients with RRMM who received bendamustine combination regimen was 4 lines, and the median course of treatment was 3 (1-8). The median follow-up time after bendamustine treatment started was 5.3(1.3-9.2)months. Among the 16 cases, the disease control rate (DCR), overall response rate(ORR), and ≥ very good partial remission (VGPR) rate were 13/16, 5/16, 4/16 respectively. The median PFS was 4.9 months. Among them, the ORR of bendamustine combined with immunomodulators was higher. AEs were anemia, leukopenia, neutropenia, thrombocytopenia and fatigue. No patients who stopped treatment and adjusted the dose due to AEs.Conclusions:Bendamustine combination regimen is an effective and safe regimen for relapsed/refractory multiple myeloma.
